Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma

• Status: Completed
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Phase II clinical trial assessing efficacy and toxicity of pretargeted radioimmunotherapy using anti-CEAxanti-DTPA bispecific antibody and di-DTPA-131I peptide in patients with reccurrence of medullary thyroid carcinoma (abnormal calcitonin level and biomarkers doubling time lower than 5 years)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nantes University Hospital
• Treatments: Antibodies; Antibodies, Bispecific

Criteria

Inclusion Criteria:

• 18 -75 years

• Karnofsky ≥ 70%

• Histological diagnosis of medullary thyroid carcinoma

• Calcitonin serum level Ê 100 pg/ml and Calcitonin or CEA doubling time £ 5 years

• Normal liver and renal functions

• Granulocytes ≥ 1500/mm3 and platelets ≥ 150 000/mm3

• No immunization

• Consent form signed